Accelerate Diagnostics Inc
AXDX
Market Cap$19.5M
Close$
$1.86
141.9% upside
Current Fair Value
141.9% upsideUndervalued by 141.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $19.50 Million |
|---|---|
| Enterprise Value | - |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $0.0 |
| Beta | 0.12 |
| Outstanding Shares | 21,664,387 |
| Avg 30 Day Volume | 83,443 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 0.0 |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | - |
| Debt to Equity | - |
Revenue Sources
No data
ESG Score
No data
About Accelerate Diagnostics Inc
CEO: John Phillips Accelerate Diagnostics, Inc. is an in vitro diagnostics company dedicated to providing solutions for the global challenges of antibiotic resistance and sepsis. The Accelerate Pheno® system and Accelerate PhenoTest® BC kit combine several...